The clinicopathologic features of molecular apocrine breast cancer

Yoon Jin Cha, Woo Hee Jung, Ja Seung Koo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: To elucidate the clinicopathologic features and their implications on the immunohistochemistry in cases of molecular apocrine breast cancer (MABC). Methods: Immunohistochemical (IHC) staining for estrogen receptor (ER), human epidermal growth factor receptor 2 (HER-2), cytokeratin (CK) 5/6, epidermal growth factor receptor (EGFR), androgen receptor (AR), gammaglutamyltrasferase 1 (GGT1) and Ki-67 was performed on tissue microarray breast cancer samples from 204 patients. Phenotypes of breast cancer were divided based on the IHC status of ER, AR and GGT1 into the following: luminal type, ER positive and AR and/or GGT1 positive; basal type, ER, AR, and GGT1 negative; non-basal type, ER positive and AR and GGT1 negative; and MABC type, ER negative and AR and/or GGT1 positive. Results: In our series of patients (n=204), there were 26 cases of MABC. Besides, there were 18, 60, and 100 cases of luminal type, basal type and non-basal type, respectively. The MABC demonstrated apocrine histology and a higher prevalence of HER-2 positivity than other phenotypes. With the basal type, the MABC manifested a more frequent expression of CK5/6 and EGFR and a higher Ki-67 index than other phenotypes (p<0.001). There were no significant differences in patient prognosis between the phenotypes of breast cancer. Conclusions: MABC are distinguishable from other phenotypes based on the apocrine histology and a higher expression rate of HER-2.

Original languageEnglish
Pages (from-to)169-176
Number of pages8
JournalKorean Journal of Pathology
Volume46
Issue number2
DOIs
Publication statusPublished - 2012

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'The clinicopathologic features of molecular apocrine breast cancer'. Together they form a unique fingerprint.

  • Cite this